Rationalization of the Acute Pancreatitis Destructive Forms Intensive Therapy: Detoxification and Nutritional Support Correction on the Basis of the Haemofiltration Membrane Technology
- Authors: 1, 1, 1, 1
-
Affiliations:
- N.N. Burdenko Voronezh State Medical Academy, 10 Studencheskaia Str., Voronezh, 394036, Russian Federation
- Issue: Vol 7, No 3 (2014)
- Pages: 208-213
- Section: Original articles
- URL: https://vestnik-surgery.com/journal/article/view/573
- DOI: https://doi.org/10.18499/2070-478X-2014-7-3-208-213
- ID: 573
Cite item
Full Text
Abstract
The purpose of the study Improving the efficacy of intensive therapy of severe acute pancreatitis by optimizing its detoxication component based on an prolonged high-volume veno-venous hemofiltration.
Materials and methods Research materials presented are 64 patients with necrotic form of severe pancreatitis and 70 patients with edematous form of its desease. Total number of examined patients amounted to 134 people. Among the investigated contingent by each studied form of acute pancreatitis were identified the main and the control groups (32 and 35 people respectively). In the control groups used traditional program of intensive therapy. In the main groups used developed detoxication program besides the traditional intensive therapy.
Methods of research are presented selective clinical, biochemical, hematological and statistical techniques.
Results and their discussion Obtained results represent an improvement antitoxic potential and nutritional status of patients with necrotizing pancreatitis due to application of the developed program of monodetoxication. Proved the possibility of prevention the transformation of edematous in necrotic form of severe pancreatitis due to an optimized use of haemofiltration technology. All of identified intergroup differences have a high level of statistical significance.
Conclusion The obtained results allow: statistically justified to consider a elaborated detoxication program as a way to optimize the pancreonecrosis intensive therapy; recommend it to practical use.
About the authors
N.N. Burdenko Voronezh State Medical Academy, 10 Studencheskaia Str., Voronezh, 394036, Russian Federation
Author for correspondence.
Email: oleg-stulikov@yandex.ru
candidate for a PhD in medicine of the anesthesiology and reanimatology chair of N.N. Burdenko Voronezh State Medical Academy Institute of additional postgraduate education (VSMA)
N.N. Burdenko Voronezh State Medical Academy, 10 Studencheskaia Str., Voronezh, 394036, Russian Federation
Email: gladkichigor@rambler.ru
a candidate for a PhD in medicine of the anesthesiology and reanimatology chair of VSMA
N.N. Burdenko Voronezh State Medical Academy, 10 Studencheskaia Str., Voronezh, 394036, Russian Federation
Email: mail@vestnik-surgery.com
a postgraduate student (aspirant) of the anesthesiology and reanimatology chair of VSMA
N.N. Burdenko Voronezh State Medical Academy, 10 Studencheskaia Str., Voronezh, 394036, Russian Federation
Email: lavr@okb.vrn.ru
MD, Prof. of the anesthesiology and reanimatology chair of VSMA
References
- Cole L. [A phase II randomized, controlled trial of continuous hemofiltration in sepsis [Faza II randomizirovannoye kontroliruyemoye issledovaniye nepreryvnoy gemofil'tratsii pri sepsise]. Crit. Care Med., 2002; 30(1): 100-106.
- Marino P.L. The ICU Book [ ICU Kniga]. William & Wilkins, 1998; 639.
- Wald R. Best Mode for clearance in critically ill patients with acute kidney injury (Omak) - a pilot randomized controlled trial hemofiltration than hemodialysis [Optimal'nyy rezhim klirensa bol'nykh v kriticheskom sostoyanii s ostroy pochechnoy travmoy (OMAKI) - pilot randomizirovannoye kontroliruyemoye issledovaniye gemofil'tratsii po sravneniyu s gemodializom.]. Canadian Critical Care Trials Group project, 2012; 39-43.
- Berlot G. Plasmapheresis in sepsis. Contribution Nephrology [Plazmaferez pri sepsise. Vklad nefrologii] 2001; 132: 391-399.
- Smith D.F. Committee on Emergency Medical Services updates [Komitet po chrezvychaynoy situatsii Meditsinskiye uslugi obnovleniya] Brit. Columbia Med. J., 2001; 1: 28-29.